Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524585 | 0.90 | PTK2 (0.45) | CNR2PTK2GSK3AGSK3BBTK | |
| SCHEMBL15524831 | 0.87 | EGFR (0.46) | CNR2BTKSTAT6 | |
| SCHEMBL15524495 | 0.85 | FLT4 (0.48) | CNR2PTK2GSK3AGSK3BCDC7 | |
| SCHEMBL15524665 | 0.84 | GSK3A (0.40) | CNR2PTK2GSK3AGSK3BCDC7 | |
| SCHEMBL12478690 | 0.82 | PTK2 (0.53) | PTK2GSK3AGSK3B | |
| SCHEMBL15524830 | 0.82 | PTK2 (0.49) | PTK2 | |
| SCHEMBL15524693 | 0.81 | JAK3 (0.45) | PTK2GSK3AGSK3B | |
| SCHEMBL12478740 | 0.81 | PTK2 (0.53) | PTK2STAT6 | |
| SCHEMBL14577403 | 0.81 | PTK2 (0.43) | PTK2GSK3AGSK3BCDC7ROCK2 | |
| SCHEMBL12478992 | 0.81 | PTK2 (0.51) | PTK2STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | GOT1, AADAT, ADH1A | CNR2 3404/4885PTK2 3451/4885GSK3A 4470/4885 |
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | CNR2 1834/4885PTK2 240/4885GSK3A 446/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | CNR2 1810/4885PTK2 260/4885GSK3A 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.